DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

Gilead Sciences (NASDAQ: GILD)

92.90 -15.55 (-14.34%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $92.90 -14.34%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $96.73
Previous Close $108.45
Daily Range $92.45 - $98.07
52-Week Range $63.50 - $116.83
Market Cap $140.2B
P/E Ratio 19.23
Dividend (Yield) $0.00 (0.0%)
Volume 72,127,666
Average Daily Volume 15,457,931
Current FY EPS $7.91





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

Why Gilead Sciences Shares Tumbled Today

Gilead Sciences shares fell sharply on concerns that competition from AbbVie's hepatitis C drug puts its market share at risk.

AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst Blog

Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog

Jim Cramer's 'Mad Money' Recap: Biotech Sector Havoc Can't Be Ignored

Commentary On Gilead Sciences' Recent Plunge

Bulls Make New Record High Despite Biotech Blues

Today's financial recap and tomorrow's financial outlook.

Week Ahead Market Report: December 22, 2014

Express Scripts Knocks Gilead's Hepatitis C Drug in Favor of AbbVie

Why I Am Not Selling Gilead

Monday's ETF Movers: EEM, BBH

See More GILD News...

GILD's Top Competitors

GILD $92.90 (-14.34%)
Current stock: GILD
AMGN $164.53 (-3.31%)
Current stock: AMGN
CELG $113.50 (-3.14%)
Current stock: CELG
$0.00 (0.00%)
Current stock: